8-K: Cocrystal Pharma Amends Bylaws to Adjust Shareholder Meeting Quorum

Cocrystal Pharma, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of the aggregate voting power of outstanding shares.

Summary

• Cocrystal Pharma, Inc.'s Board of Directors approved an amendment to the company's Amended and Restated Bylaws on June 17, 2025.
• The amendment changes the quorum requirement for stockholder meetings to one-third of the aggregate voting power of the outstanding shares of all classes or series of voting stock then entitled to vote, represented in person or by proxy.
• This new quorum requirement also applies to specific items of business required to be voted on by a particular class or series of stock, where one-third of that class's voting power will constitute a quorum.
• The amendment specifies that if a quorum is present, the affirmative vote of the majority of the aggregate voting power of shares present shall be the act of the stockholders, unless otherwise provided, with directors elected by a plurality of such shares.
• The amendment clarifies that once a quorum is established, subsequent withdrawal of stockholders will not affect the validity of actions taken.
• The holders of a majority of voting shares represented at a meeting, even without a quorum, may adjourn the meeting to a date within 60 days from the record date.

Sentiment

Score: 5

Explanation: The document reports a procedural corporate governance change. While it could make shareholder meetings easier to conduct (positive for efficiency), it also reduces the required shareholder representation for a quorum (potentially negative for broad shareholder influence). Overall, it's a neutral event regarding the company's operational or financial performance.

Positives

• The reduced quorum requirement may make it easier for Cocrystal Pharma to achieve a quorum and conduct shareholder meetings, potentially improving operational efficiency for corporate actions requiring shareholder votes.

Negatives

• The reduction in the required shareholder representation for a meeting to be valid could potentially diminish the collective influence of a larger portion of shareholders, as decisions can be made with a smaller percentage of total voting power.

Risks

• Decisions at stockholder meetings could be made with a smaller percentage of total shareholder votes, potentially leading to less broad consensus or perceived disenfranchisement among some shareholders.
• A lower quorum might increase the risk of a minority of shareholders exerting disproportionate influence over corporate decisions.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on a corporate governance amendment.

Management Comments

• The report was signed by James Martin, Chief Financial Officer and Co-Chief Executive Officer of Cocrystal Pharma, Inc.

Industry Context

This amendment is a corporate governance change, a common procedural adjustment for publicly traded companies. It does not directly relate to broader industry trends in the pharmaceutical or biotechnology sector, but rather to internal operational mechanics for shareholder engagement.

Comparison to Industry Standards

• Many public companies have quorum requirements ranging from 25% to 50% of outstanding shares. A one-third (approximately 33.3%) quorum is within a common range, though it represents a reduction if the previous requirement was higher (e.g., a majority).
• Specific comparable companies or projects are not relevant as this is a general corporate governance matter rather than a financial or operational result.

Corporate Governance

Stakeholder Impact

• Shareholders: The change in quorum requirement directly impacts shareholders by altering the threshold for valid stockholder meetings and potentially affecting the collective influence required for corporate decisions.

Key Dates

Keywords

Cocrystal Pharma, bylaws, quorum, corporate governance, shareholder meeting, COCP, SEC filing, 8-K